ixazomib

medtigo

ixazomib

Brand Name :

Ninlaro

Synonyms :

ixazomib

Class :

Antineoplastic agents and proteasome inhibitors

Action and Spectrum

Actions and Spectrum:

Actions:

ixazomib works by selectively inhibiting the proteasome, which disrupts the normal protein breakdown process in cells. It leads to the accumulation of damaged or misfolded proteins in cancer cells, causing them to die.

Spectrum:

ixazomib is approved by the FDA for treating multiple myeloma, a type of blood cancer. It is combined with other medications, such as lenalidomide and dexamethasone, in patients who have received at least one prior therapy. ixazomib may also be used as a maintenance therapy to help delay the progression of multiple myeloma.

Dosing & Uses

Drug Interaction

Adverse Reaction

Adverse drug reactions:

Frequency defined:

>10%

Thrombocytopenia

Neutropenia

Diarrhea

Constipation

Peripheral neuropathies

Nausea

Thrombocytopenia, grade 3-4

Neutropenia, grade 3-4

Peripheral edema

Vomiting

Back pain

Upper respiratory tract infection

Rash

1% to 10%

Diarrhea, grade 3

Blurred vision

Conjunctivitis

Dry eye

Herpes zoster, without antiviral prophylaxis

Rash, grade 3

Peripheral edema

Peripheral neuropathies, grade 3

Nausea, grade 3

Vomiting, grade 3

Black Box Warning

Contraindication / Caution

Contraindication/Caution:

Ixazomib is a prescription medication that is generally safe and well-tolerated, but like all medications, it can cause side effects and interact with other drugs. Therefore, it is essential to take certain precautions and to be aware of any contraindications or cautions before taking ixazomib. Some of the main contraindications and cautions for ixazomib include:
Hypersensitivity: drug should not be used in patients with known hypersensitivity to ixazomib or its components. Hypersensitivity reactions can range from mild to severe, including symptoms such as rash, itching, hives, difficulty breathing, and swelling of the face or throat.
Pregnancy and breastfeeding ixazomib can cause fetal harm and is not recommended during pregnancy. Women of childbearing age should use effective contraception while taking ixazomib and for at least 90 days after stopping treatment. It is unknown if ixazomib is excreted in human milk, so avoid breastfeeding during treatment and for at least 90 days after the last dose.
Hepatic impairment: ixazomib is metabolized in the liver, so caution is advised in patients with hepatic impairment. Dose adjustments may be necessary for the patients with moderate to severe hepatic impairment.
Renal impairment: ixazomib is excreted in the feces, so it is unlikely to accumulate in patients with renal impairment. However, caution is advised in patients with severe renal impairment or end-stage renal disease, and dose adjustments may be necessary.
Drug interactions: ixazomib may interact with other medications, such as strong CYP3A4 inhibitors and inducers, which can increase or decrease the levels of ixazomib in the body. It is important to discuss all medications and supplements with your healthcare provider before starting ixazomib.
Peripheral neuropathy: ixazomib can cause peripheral neuropathy. Patients who experience symptoms such as tingling, numbness, or pain in their hands or feet should notify their healthcare provider, as dose adjustments or medication discontinuation may be necessary.

Pregnancy / Lactation

Pregnancy warnings:   

Not indicated to be administered during pregnancy, as the gestating females who intake mercaptopurine are prone to fetal damage

Breastfeeding warnings:  

The data for drug and its metabolites secretion in breastmilk is unknown, but for the sake of precaution, lactating females shouldn’t breastfeed during and one week later the treatment after the mercaptopurine dose

Pregnancy Categories:     

Category A: Satisfactory and well-controlled studies show no risk to the fetus.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women     
Category C: No adequate evidence for a result in humans must take care of potential risks in pregnant women     
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits     
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women. Better alternatives are preferred.  
Category N: There is no data available for the drug under this category

Pharmacology

Pharmacology:

ixazomib is a proteasome inhibitor that inhibits the chymotrypsin-like activity of the 20S proteasome. The 20S proteasome is a large protein complex involved in the degradation of intracellular proteins that are no longer needed, damaged, or misfolded. By inhibiting the proteasome, ixazomib blocks the degradation of these proteins, leading to the accumulation of toxic protein aggregates that can cause cancer cell death.

ixazomib is a reversible proteasome inhibitor, and its activity depends on the presence of the β5 subunit in the proteasome. It selectively binds to the β5 subunit, preventing the regular enzymatic activity of the proteasome.

Pharmacodynamics:

pharmacodynamics of ixazomib involve its ability to inhibit the proteasome selectively and reversibly, leading to the accumulation and subsequent death of abnormal proteins in multiple myeloma cells. Additionally, ixazomib has anti-angiogenic effects that can reduce blood vessel formation and tumor growth. Pharmacokinetics:

The pharmacokinetics of ixazomib are as follows:

Absorption

ixazomib is rapidly absorbed after oral administration, with a median time to peak concentration of approximately 1-2 hours. The bioavailability of ixazomib is approximately 58%, and its absorption is not affected by food.

Distribution

ixazomib is extensively distributed in the body, with a volume of distribution of approximately 283 L. It is highly bound to plasma proteins, primarily to alpha-1-acid glycoprotein (AAG), with a binding capacity of 99.7%.

Metabolism

ixazomib is primarily metabolized in the liver by cytochrome P450 (CYP) enzymes, primarily CYP3A4, and to a lesser extent by CYP1A2 and CYP2C19. It undergoes hydrolysis to its primary metabolite, MLN9708, which is also pharmacologically active. MLN9708 is further metabolized by oxidation, hydrolysis, and glucuronidation, and the metabolites are eliminated from the body. Elimination/Excretion

ixazomib is eliminated from the body primarily through the feces (44%), with approximately 29% of the dose excreted in the urine. The elimination half-life of ixazomib is approximately 9.5 days.

Adminstartion

Administration:

ixazomib is used in the treatment of multiple myeloma, which is a blood cancer that affects the plasma cells.

ixazomib is typically used for treating multiple myeloma. It has improved progression-free survival and overall response rates in clinical studies, making it a valuable treatment option for patients with multiple myeloma.

Overall, ixazomib is used to help manage the symptoms of multiple myeloma and to help slow the progression of the disease, thereby improving outcomes and quality of life for patients.

Patient Information Leaflet

Patient information leaflet

Generic Name: ixazomib

Pronounced: ix-AZ-oh-mib

Why do we use ixazomib?

ixazomib is used in the treatment of multiple myeloma, which is a type of blood cancer that affects the plasma cells. ixazomib is typically used in combination with other medications such as lenalidomide and dexamethasone for the treatment of multiple myeloma.

It has been shown to improve progression-free survival and overall response rates in clinical studies, making it a valuable treatment option for patients with multiple myeloma. Overall, ixazomib is used to help manage the symptoms of multiple myeloma and to help slow the progression of the disease, thereby improving outcomes and quality of life for patients.

ixazomib

No data available for drug.

DRUG INTERACTION

ixazomib

&

ixazomib +

Contraindicated

Serious Use Alternative

Monitor Closely

Minor

ixazomib

No data available for drug.

DRUG INTERACTION

ixazomib

&

ixazomib +

Contraindicated

Serious Use Alternative

Monitor Closely

Minor

medtigo

ixazomib

Brand Name :

Synonyms :

Class :

Action and Spectrum

Dosing & Uses

Drug Interaction

Adverse Reaction

Black Box Warning

Contraindication / Caution

Pregnancy / Lactation

Pharmacology

Adminstartion

Patient Information Leaflet

CONTACT INFORMATION

ADDRESS

JOIN THE FASTEST GROWING HEALTHCARE COMMUNITY!